(S037) Irradiated Human Endothelial Progenitor Cells Induce Bystander Killing in Human Non–Small-Cell Lung and Pancreatic Cancer Cells

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

These data provide evidence that irradiated hEPCs can induce strong bystander killing in A549 and MIA PaCa-2 cancer cells that is mediated by TNF-α and TGF-β.

William T. Turchan, BS, Ronald H. Shapiro, MD, Garret V. Sevigny, BS, Helen Chin-Sinex, BS, Benjamin Pruden, MD, Marc S. Mendonca, PhD; Indiana University School of Medicine

BACKGROUND: Using A549 tumor xenographs, we found that coinjection of CBM3 human endothelial progenitor cells (hEPCs) with A549 non–small-cell lung cancer (NSCLC) cells significantly increased the tumor growth rate compared with A549 cells alone but, paradoxically, also increased A549 tumor cure after a single 5-Gy dose of x-rays (P < .05). We hypothesized that irradiated hEPCs may be inducing bystander killing in A549 cancer cells in tumor xenographs, thus improving tumor cure.

METHODS: Using dual-chamber Transwell dishes, we tested whether medium from irradiated CBM3 and CBM4 hEPCs would induce bystander cell killing in A549 NSCLC cells and, as an additional control, in MIA PaCa-2 human pancreatic cancer cells. The CBM3 and CBM4 hEPCs were plated into the upper Transwell chamber, and the A549 or MIA PaCa-2 cells were plated in the lower Transwell chamber. The top inserts with the CBM3 or CBM4 hEPCs were subsequently removed, irradiated, and then placed back into the Transwell dish for 3 hours to allow for diffusion of any potential bystander factors from the irradiated hEPCs in the upper chamber through the permeable membrane to the unirradiated cancer cells in the lower chamber. After the 3-hour incubation, the cancer cells were replated for clonogenic survival.

RESULTS: The data clearly showed that exposure to the medium from irradiated CBM3 and CBM4 hEPCs induced significant bystander killing and decreased the surviving fraction of A549 and MIA PaCa-2 cells to 0.46 (46%) ± 0.22 and 0.74 ± 0.07 (74%), respectively (P < .005 and P < .0001). Moreover, antibody depletion studies demonstrated that the bystander killing that was induced in both A549 and MIA PaCa-2 cells was mediated by the cytokines TNF-α and TGF-β (P < .05).

CONCLUSION: These data provide evidence that irradiated hEPCs can induce strong bystander killing in A549 and MIA PaCa-2 cancer cells that is mediated by TNF-α and TGF-β.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content